Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 18/20 | 0.46 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.45 |
| ▸ | RXRG | P48443 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793355 | 1.00 | ESR1 (0.46) | ESR1RXRARXRBRXRGS1PR1 | |
| SCHEMBL793354 | 1.00 | ESR1 (0.46) | ESR1RXRARXRBRXRGS1PR1 | |
| SCHEMBL18720914 | 0.92 | RXRA (0.44) | ESR1RXRARXRBRXRG | |
| SCHEMBL771229 | 0.91 | RXRA (0.41) | ESR1RXRARXRBRXRGS1PR1 | |
| SCHEMBL30646348 | 0.91 | RXRA (0.41) | ESR1RXRARXRBRXRGS1PR1 | |
| SCHEMBL18720908 | 0.91 | RXRA (0.45) | ESR1RXRARXRBRXRG | |
| SCHEMBL18720901 | 0.91 | RXRA (0.41) | ESR1RXRARXRBRXRGS1PR1 | |
| SCHEMBL22656814 | 0.88 | RXRA (0.47) | ESR1RXRARXRBRXRG | |
| SCHEMBL22656810 | 0.88 | RXRA (0.47) | ESR1RXRARXRBRXRG | |
| SCHEMBL29536400 | 0.88 | RXRA (0.47) | ESR1RXRARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| US-9868704-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | GENENTECH, INC. (US) | 2016-10-13 | — | — | US | disclosed |
| US-9399646-B2 | Estrogen receptor modulators and uses thereof | GENENTECH, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2616445-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2013-07-24 | — | — | EP | disclosed |
| US-8455534-B2 | Estrogen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-01-10 | — | — | US | disclosed |
| WO-2012037411-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012037410-A9 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012037410-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012037411-A2 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231333-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885RXRA 29/4885RXRB 37/4885 |
| US-20130012561-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885RXRA 34/4885RXRB 38/4885 |
| US-20160297767-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | ESR1 4/4885RXRA 34/4885RXRB 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.